Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment

Journal of Clinical Oncology

Volumn 26, Issue 30, 2008, Pages 4928-4933

  Köllermann, Jens ^a   Weikert, Steffen ^a   Schostak, Martin ^a   Kempkensteffen, Carsten ^a   Kleinschmidt, Klaus ^a   Rau, Thomas ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CYTOKERATIN ANTIBODY; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; ANILIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; DISEASE FREE SURVIVAL; DISEASE MARKER; DISSEMINATED CANCER; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BIOPSY; BONE MARROW CANCER; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSTATE TUMOR; TUMOR EMBOLISM;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; NITRILES; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 54449101194     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.0441     Document Type: Article

References (43)

1. Allsbrook WC Jr, Mangold KA, Johnson MH, et al: Interobserver reproducibility of Gleason grading of prostatic carcinoma: General pathologist. Hum Pathol 32:81-88, 2001
2. Djavan B: Gleason scores from prostate biopsies obtained with 18gauge biopsy needles poorly predict gleason scores of radical prostatectomy specimens. Curr Opin Urol 8:441, 1998
3. Gleason DF: Undergrading of prostate cancer biopsies: A paradox inherent in all biologic bivariate distributions. Urology 47:289-291, 1996
4. Stamey TA, Johnstone IM, McNeal JE, et al: Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with postradical prostatectomy cancer morphology: Prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol 167:103-111, 2002
5. Graefen M, Augustin H, Karakiewicz PI, et al: Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence after radical prostatectomy. Urologe A 42:685-692, 2003
6. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
7. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997
8. Graefen M, Augustin H, Karakiewicz PI, et al: Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol 43:6-10, 2003
9. Kattan MW, Potters L, Blasko JC, et al: Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 58:393-399, 2001
10. Penson DF, Albertsen PC: Lessons learnt about early prostate cancer from large scale databases: Population-based pearls of wisdom. Surg Oncol 11:3-11, 2002
11. Stamey TA: The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA. BJU Int 94:963-964, 2004
12. Cristofanilli M, Mendelsohn J: Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy? Proc Natl Acad Sci U S A 103:17073-17074, 2006
13. Pantel K, Alix-Panabieres C: The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 4:62-63, 2007
14. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4:448-456, 2004
15. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005
16. Köllermann J, Heseding B, Helpap B, et al: Comparative immunocytochemical assessment of isolated carcinoma cells in lymph nodes and bone marrow of patients with clinically localized prostate cancer. Int J Cancer 84:145-149, 1999
17. Mansi JL, Berger U, Wilson P, et al: Detection of tumor cells in bone marrow of patients with prostatic carcinoma by immunocytochemical techniques. J Urol 139:545-548, 1988
18. Pantel K, Aignherr C, Köllermann J, et al: Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. Eur J Cancer 31A:1627-1632, 1995
19. Pfitzenmaier J, Ellis WJ, Hawley S, et al: The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 25:214-220, 2007
20. Weckermann D, Muller P, Wawroschek F, et al: Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: Detection and prognostic value. J Urol 166:699-703, 2001
21. Weckermann D, Wawroschek F, Krawczak G, et al: Does the immunocytochemical detection of epithelial cells in bone marrow (micrometastasis) influence the time to biochemical relapse after radical prostatectomy? Urol Res 27:285-290, 1999
22. Wood DP Jr, Banerjee M: Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 15:3451-3457, 1997
23. Fehm T, Braun S, Müller V, et al: A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 107:885-892, 2006
24. Braun S, Pantel K, Müller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533, 2000
25. Bianco FJ Jr, Wood DP Jr, Gomes de Oliveira J, et al: Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 49:235-242, 2001
26. Gao CL, Dean RC, Pinto A, et al: Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. J Urol 161:1070-1076, 1999
27. Köllermann J, Feek U, Muller H, et al: Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol 38:714-720, 2000
28. Köllermann MW, Pantel K, Enzmann T, et al: Supersensitive PSA monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow. Eur Urol 34:318-324, 1998
29. Köllermann MW, Sprenk P, Mühlfait V, et al: Downstaging of stage C prostatic carcinoma by inductive chemo-hormonal therapy? Eur Urol 24:337-341, 1993
30. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166:500-506, 2001
31. Köllermann J, Caprano J, Budde A, et al: Prolonged neoadjuvant endocrine therapy of prostate cancer: PSA failure rate influenced by decreased testosterone production after cessation of endocrine therapy? J Urol 169:278, 2003 (suppl)
32. Carroll PR, Kantoff PW, Balk SP, et al: Overview consensus statement: Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60:1-6, 2002
33. Civantos F, Marcial MA, Banks ER, et al: Pathology of androgen deprivation therapy in prostate carcinoma: A comparative study of 173 patients. Cancer 75:1634-1641, 1995
34. Helpap B, Köllermann J: Therapy induced regressive changes of prostate cancer. Pathologe 25:461-468, 2004
35. Smith DM, Murphy WM: Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): Distinction from poor tumor differentiation. Cancer 73:1472-1477, 1994
36. Klein CA, Blankenstein TJ, Schmidt-Kittler O, et al: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360:683-689, 2002
37. Schmidt-Kittler O, Ragg T, Daskalakis A, et al: From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A 100:7737-7742, 2003
38. Solakoglu O, Maierhofer C, Lahr G, et al: Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A 99:2246-2251, 2002
39. Alix-Panabieres C, Vendrell JP, Pelle O, et al: Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53:537-539, 2007
40. Kraus J, Pantel K, Pinkel D, et al: High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer 36:159-166, 2003
41. Meng S, Tripathy D, Shete S, et al: HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101:9393-9398, 2004
42. Pantel K, Enzmann T, Köllermann J, et al: Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 71:521-525, 1997
43. Wood DP Jr, Beaman A, Banerjee M, et al: Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Clin Cancer Res 4:2119-2123, 1998